Optimizing Research with Decentralized Strategies
WHAT YOU NEED TO KNOW TODAY
We are seeing unprecedented changes since the appearance of the SARS-CoV-2 virus, but the trend towards decentralized trials was already underway prior to COVID-19. The pandemic is changing research conditions for both sites and patients, dramatically affecting the continuity of trials globally.
With this sudden disruption, the industry has been introduced to new regulatory guidelines designed to keep drug development on track and ensure trials meet critical milestones in the face of logistical and operational hurdles.
As a trusted leader in the decentralized trial space, PPD frequently publishes insights into these trends, the solutions that are available, and what the options and best approaches are for sponsors with ongoing and planned clinical trials. We invite you to click on the link below to read a newly published perspective.